STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANIK
  4. [Form 4] Anika Therapeutics, Inc. Insider Trading Activity

Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Richard Stephen reported acquisition or exercise transactions in this Form 4 filing.

Anika Therapeutics director Richard Stephen received a grant of 10,402 restricted stock units on June 18, 2026. Each RSU equals one share of common stock and vests in full on the earlier of the 2027 annual shareholder meeting or June 18, 2027. Following this award, he holds 58,273 shares directly.

Positive

  • None.

Negative

  • None.
Insider Richard Stephen
Role null
Type Security Shares Price Value
Grant/Award Common Stock 10,402 $0.00 --
Holdings After Transaction: Common Stock — 58,273 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 10,402 RSUs Restricted stock unit award on June 18, 2026
Holdings after transaction 58,273 shares Direct common stock holdings following RSU grant
RSU grant price $0.00 per share Compensation award with no cash paid per share
RSU vesting date Earlier of 2027 annual meeting or June 18, 2027 RSUs vest in full by this time
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Company's common stock."
vest in full financial
"The RSUs vest in full on the earlier of the 2027 annual meeting..."
annual meeting of the Company's stockholders financial
"on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Richard Stephen
(Last)(First)(Middle)
C/O ANIKA THERAPEUTICS, INC.
32 WIGGINS AVENUE
(Street)
BEDFORD MASSACHUSETTS 01730
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A10,402(1)A$058,273D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.
/s/ Stephen Richard06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Anika Therapeutics (ANIK) report for Richard Stephen?

Anika Therapeutics reported that director Richard Stephen received a grant of 10,402 restricted stock units. These RSUs are a form of stock-based compensation and each unit represents the right to receive one share of Anika’s common stock if vesting conditions are met.

When do Richard Stephen’s new RSUs at Anika Therapeutics (ANIK) vest?

The 10,402 RSUs granted to Richard Stephen vest in full on the earlier of the 2027 annual shareholder meeting or June 18, 2027. Vesting means the RSUs convert into common shares that he can then own outright, subject to plan terms.

How many Anika Therapeutics (ANIK) shares does Richard Stephen hold after this Form 4?

Following the RSU grant, Richard Stephen is reported to hold 58,273 shares of Anika Therapeutics common stock directly. This figure reflects his position after the award, providing context on his total direct equity stake in the company as of the transaction date.

Is Richard Stephen’s Anika Therapeutics (ANIK) Form 4 a market buy or sell?

The Form 4 shows a grant of restricted stock units, not a market buy or sell. The transaction is coded as an acquisition via award, with no cash price per share, indicating compensation rather than an open-market trade of Anika Therapeutics stock.

What does the RSU footnote in Anika Therapeutics (ANIK) Form 4 explain?

The footnote explains that the reported shares are restricted stock units, each representing a contingent right to receive one share of common stock. It also clarifies the vesting schedule, stating they vest in full by the earlier of the 2027 meeting or June 18, 2027.